Anti-proinflammatory effects of sirolimus on human islet preparations

Transplantation

Volumn 86, Issue 1, 2008, Pages 46-53

  Mita, Atsuyoshi ^a,b   Ricordi, Camillo ^a,c,d   Miki, Atsushi ^a   Barker, Scott ^a   Haertter, Ross ^a   Hashikura, Yasuhiko ^e   Miyagawa, Shin Ichi ^b   Burke, George W ^c,d   Inverardi, Luca ^a,c   Ichii, Hirohito ^a,c,d  

^a DIABETES RESEARCH INSTITUTE   (United States)

^b Department of Surgery   (Japan)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d JACKSON MEMORIAL HOSPITAL   (United States)

^e SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokine; Cytokine; Islet; Rapamycin; Transplantation

Indexed keywords

CHEMOKINE; CYTOKINE; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CCL2 PROTEIN, HUMAN; CCL4 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL SELECTION; CELL SURVIVAL; CELL VIABILITY; CONTROL GROUP; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG IMPURITY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; MACROPHAGE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SUPPLEMENTATION; DRUG EFFECT; METABOLISM; PANCREAS DUCT; PANCREAS ISLET; TIME; TISSUE CULTURE TECHNIQUE;

ANTI-INFLAMMATORY AGENTS; CELL SURVIVAL; CHEMOKINE CCL2; CHEMOKINE CCL4; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MACROPHAGES; PANCREATIC DUCTS; SIROLIMUS; TIME FACTORS; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49849090331     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817c79c0     Document Type: Article

References (44)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710.
3. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003; 237: 741.
4. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosup-pression: Miami experience. Am J Transplant 2005; 5: 2037.
5. Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10: 330.
6. Terada N, Lucas JJ, Szepesi A, et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993; 154: 7.
7. Kneteman NM, Lakey JR, Wagner T, et al. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61: 1206.
8. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001; 3: 393.
9. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731.
10. Hui H, Khoury N, Zhao X, et al. Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 2005; 54: 424.
11. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006; 55: 2429.
12. Marcelli-Tourvieille S, HubertT,Moerman E, et al. In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation 2007; 83: 532.
13. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413.
14. Ichii H, Sakuma Y, Pileggi A, et al. Shipment of human islets for transplantation. Am J Transplant 2007; 7: 1010.
15. Desai NM, Goss JA, Deng S, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: Local immuno-suppression or islet toxicity? Transplantation 2003; 76: 1623.
16. Shapiro AM, Gallant HL, Hao EG, etal. The portal immunosuppressive storm: Relevanceto islet transplantation?Ther Drug Monit 2005; 27: 35.
17. Gmyr V, Belaich S, Muharram G, et al. Rapid purification of human ductal cells from human pancreatic fractions with surface antibody CA19-9. Biochem Biophys Res Commun 2004; 320: 27.
18. Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005; 5: 21.
19. Ichii H, Inverardi L, Pileggi A, et al. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant 2005; 5: 1635.
20. RicordiC, Zeng YJ, AlejandroR,et al.In vivo effect ofFK506onhuman pancreatic islets. Transplantation 1991; 52: 519.
21. Zahr E, Molano RD, Pileggi A, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007; 84: 1576.
22. Delaney CA, Pavlovic D, Hoorens A, et al. Cytokines induce deoxyri-bonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 1997; 138: 2610.
23. Hanley S, Liu S, Lipsett M, et al. Tumor necrosis factor-alpha production by human islets leads to postisolation cell death. Transplantation 2006; 82: 813.
24. Bottino R, Fernandez LA, Ricordi C,etal. Transplantationofallogeneic islets of Langerhans in the rat liver: Effects of macrophage depletion on graft survival and microenvironment activation.Diabetes1998; 47: 316.
25. Berney T, Molano RD, Cattan P, et al. Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation 2001; 71: 125.
26. Arnush M,Heitmeier MR, Scarim AL, et al. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998; 102: 516.
27. Tran PO, Gleason CE, Robertson RP. Inhibition of interleukin-1beta- induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function. Diabetes 2002; 51: 1772.
28. Lee I, WangL, Wells AD,etal. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171: 6929.
29. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: Relevance in human islet transplantation. Diabetes 2002; 51: 55.
30. Giri JG, Lomedico PT, Mizel SB. Studies on the synthesis and secretion of interleukin 1. I. A 33,000 molecular weight precursor for interleukin 1. J Immunol 1985; 134: 343.
31. March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641.
32. Urban JL, Rothstein JL, Shephard MH, et al. Tumor necrosis factor: A potent mediator ofmacrophage-dependent tumor-cell killing.Haematol Blood Transfus 1987;31: 351.
33. Juang JH, Hsu BR, Kuo CH. 15-Deoxyspergualin protects the islet graft from macrophage-mediated injury. Transplant Proc 2002; 34: 1458.
34. Kaufman DB, Gores PF, Field MJ,et al. Effect of15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. Diabetes 1994; 43: 778.
35. Matsuda T, Omori K, Vuong T, et al. Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant 2005; 5: 484.
36. Mercalli A, Sordi V, Ponzoni M, et al. Rapamycin induces a caspase-independent cell death in human monocytes. Am J Transplant 2006; 6: 1331.
37. Grady T, Liang P, Ernst SA, et al. Chemokine gene expression in rat pancreatic acinar cells is an early event associated with acute pancreatitis. Gastroenterology 1997; 113: 1966.
38. Baker MS, Chen X, Rotramel A, et al. Proinflammatory cytokines induce NF-kappaB-dependent/NO-independent chemokine gene expression in MIN6 beta cells. J Surg Res 2003; 110: 295.
39. Sun LK, Reding T, Bain M, et al. Prostaglandin E2 modulates TNF-alpha-induced MCP-1 synthesis in pancreatic acinar cells in a PKA-dependent manner. Am J Physiol Gastrointest Liver Physiol 2007; 293: G1196.
40. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004; 36: 1882.
41. Barbe-Tuana FM, Klein D, Ichii H, et al. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes 2006; 55: 2437.
42. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
43. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830.
44. Bussiere CT, Lakey JR, Shapiro AM, et al. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006; 49: 2341.